nucleolar protein 12Genealiases: Nop25 · VITO · dJ37E16.7
Q-omics provides the consensus-scored NOL12 profile across patient tissues and cancer cell-line models. NOL12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NOL12 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NOL12 RNA expression shows 18,634 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where NOL12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOL12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOL12 survival associations across molecular data types. NOL12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOL12 RNA expression–survival associations across cancer types. High NOL12 expression shows unfavorable associations in KIRC, ACC and LIHC, but favorable associations in BLCA, PAAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NOL12 RNA expression.
This table summarizes NOL12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NOL12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOL12 shows higher tumor expression in KIRC, LIHC, HNSC, BLCA, COAD and STAD. The KIRC box plot shows higher NOL12 RNA expression in tumor versus normal tissue (log2 FC = +0.451, t-test p < 0.001).
This table shows molecular features associated with NOL12 in patient tissues and cancer cell lines. In patient samples, NOL12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOL12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
